Ototoxicity resulting in inner ear damage is a leading cause of acquired hearing loss worldwide. About a billion people are at risk of avoidable hearing loss, according to the World Health Organization (WHO). This could be minimized or avoided by early testing of hearing functions in the preclinical phase. While the assessment of ototoxicity is well defined for drug candidates in the hearing field (i.e., required testing for drugs that are administered by the otic route and expected to reach the middle or inner ear during clinical use), ototoxicity testing is not required for the other therapeutic areas. Unfortunately, this has resulted in more than 200 ototoxic marketed medications, and is a significant issue in hearing healthcare.
CILcare is pleased to announce that its Marketing & Business Development Director, Marie Peytavy-Izard, will be speaking on May 17th at 2:25 pm EST during the third Future of Hearing Healthcare Conference. In this presentation entitled “How to monitor ototoxicity early in drug development”, you will:
- Know & recognize ototoxic drug classes
- Discover the techniques to measure auditory functions in preclinical studies and see examples with ototoxicity studies cases
- Get insights into drug development pipeline for otoprotection and strategies for ototoxicity prevention
The Future of Hearing Healthcare conference will gather experts from the hearing care field over three days (May 17, 24, 31) to discuss topics such as AI and machine learning in hearing healthcare, inner ear therapeutics, research on OTC vs prescription devices, biometrics and sensor technology, to name a few.
Learn more about CILcare-CBSET’s expertise in GLP and non-GLP ototoxicity here.